Bevacizumab (AVASTIN®)
Agent Description
A monoclonal antibody biologic that inhibits tumoral angiogenesis to suppress tumor growth.
Mechanism of Action
Anti-angiogenesis inhibitor.
Classification
Anti-angiogenesis inhibitor, anticancer agent, monoclonal antibody.
Molecular Target
VEGF
Monograph
Approved in the US for colorectal cancer, NSCLC, RCC, GBM, ovarian cancer, cervical cancer.
View the bevacizumab package insert (PDF).
Studies of Interest
Combinations with immunotherapeutic agents.
Information collaborator would like included in investigator proposals
N/A
Genentech supports non-clinical research proposals through a separate mechanism. Please visit Genentech's Outgoing Material Transfer Agreement (MTA) Program to submit a request for a Genentech agent for non-clinical work.